Molecular Mechanism of Exercise in Cirrhosis (NCT05982769)
๐ฉบ Plain-English Summary (8th-Grade Level)
This study aims to investigate the effects of 12 weeks of resistance or endurance exercise on patients with cirrhosis. Cirrhotic patients are prone to muscle loss (sarcopenia) and ammonia build up due to liver dysfunction. The liver which in healthy patients is able to process ammonia through ureagenesis is unable to do so in cirrhosis and ammonia is taken up either by the brain causing confusion or the skeletal muscle causing muscle loss or sarcopenia. Primary sarcopenia occurs in older individuals and can be mitigated by exercise. Secondary sarcopenia occurs in response to disease such as cancer, chronic kidney disease, multiple sclerosis, and cirrhosis of all etiologies. Resistance exercise is an excellent stimulator for muscle protein synthesis and is widely used to build muscle mass and strength but has little benefit to cardiovascular function. Endurance exercise has shown to be safe in cirrhosis however there is no set prescription for cirrhosis as there is for other disease. Endurance exercise is known to promote improved cardiovascular health, improve fatigue, and generates less ammonia build up than resistance exercise. In patients with low muscle mass it is possible that endurance exercise alone will be enough to improve muscle mass. There have been few studies on exercise and cirrhosis, those that exist have shown benefits with endurance exercise. However there are even more limited studies on resistance exercise and few to no studies on the molecular mechanisms behind exercise in cirrhosis. Study visits are described fully in the protocol and consent form. After passing a screening visit patients will undergo a maximal exercise/fitness test (pre-baseline test) and other body composition measurements. After the screening and pre-baseline visit randomization will occur (2:2:1 endurance, resistance, or SOC) arrangements will be made to have the appropriate exercise equipment given to patients. Once the exercise equipment has arrived a baseline study visit will occur. After the baseline visit the endurance exercise group will cycle 3 days per week for 60 minutes under the supervision of the study team. The resistance exercise group will perform a whole body resistance workout 2 days per week for approximately 60 minutes under the supervision of a study team member. Patients in all groups will have the fitness test repeated at weeks 4, 8 and 12. After the 12 weeks of exercise the baseline visits will be repeated and after 2 weeks patients will complete one final fitness test to examine the effects of de-training.
Who can join: Review the eligibility criteria below.
Location: Cleveland Clinic โ Cleveland, Ohio
Age range: 21 Years to 65 Years
๐งช Interventions in This Study
- Endurance Training 3 times per week (BEHAVIORAL)
- Resistance Exercise (BEHAVIORAL)
- Standard of Care (BEHAVIORAL)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Cleveland Clinic โ Cleveland, Ohio
๐ Contact the Study Coordinator
Phone: (216) 318-7010
Email: dasaras@ccf.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cirrhosis, Liver
- LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study โ Ann Arbor, Michigan
- ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement โ Phoenix, Arizona
- Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease โ Ann Arbor, Michigan
- Angiotensin 2 for AKI After OLT โ Los Angeles, California
- Erlotinib for Hepatocellular Carcinoma Chemoprevention โ Dallas, Texas
- Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics โ Chandler, Arizona
Explore by condition: All Cirrhosis, Liver clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.